HANA, Hawaii, Feb. 1, 2006 (PRIMEZONE) -- Maui General Store, Inc. (OTCBB:MAUG) and Palmera Holdings, Inc. dba Trinity BioGenics, announced today that the two companies have completed their agreement to merge as of January 24. Trinity BioGenics is a biotechnology company engaged in research and development of unique adult stem cell procedures and patient-specific immune therapies with applications for various conditions and diseases, with a current clinical focus on therapies for heart disease. "This is great news for Maui General Store shareholders," stated Maui General Store CEO Richard Miller, concluding that "Stem cell research and therapies may revolutionize the way medicine is conceived and practiced in the 21st Century."
The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.
The Maui General Store logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1128